Sudubrilimab

舒度利单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameSudubrilimab

Drug Alias Name重组抗PD-L1全人源单克隆抗体注射液HS-636

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsPrimary mediastinal B cell lymphomaTriple Negative Breast NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaDiscontinued

China Registration ClassClass 1 therapeutic biologic in China

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsPrimary mediastinal B cell lymphomaTriple Negative Breast NeoplasmsNeoplasms

ATC CodeN/A